Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases
C L Bennett1, P D Weinberg, K Rozenberg-Ben-Dror
1Northwestern University and Chicago Veterans Affairs HealthCare System-Lakeside Division, Illinois 60611, USA.
Background:
Thrombotic thrombocytopenic purpura, a life-threatening multisystem disease, has been infrequently associated with use of ticlopidine, a platelet anti-aggregating agent.
Purpose:
To review 60 cases of ticlopidine-associated thrombotic thrombocytopenic purpura.
Data Sources:
Medical records, published case reports, and case reports submitted to the U.S. Food and Drug Administration.
Study Selection:
Instances of ticlopidine-associated thrombotic thrombocytopenic purpura were identified.
Data Synthesis:
Ticlopidine had been prescribed for less than 1 month in 80% of the patients, and normal platelet counts had been found within 2 weeks of the onset of thrombotic thrombocytopenic purpura in most patients. Mortality rates were higher among patients who were not treated with plasmapheresis than among those who underwent plasmapheresis (50% compared with 24%; P < 0.05).
Conclusions:
Ticlopidine use may be associated with the development of thrombotic thrombocytopenic purpura, usually within 1 month of initiation of therapy. The onset of ticlopidine-associated thrombotic thrombocytopenic purpura is difficult to predict, despite close monitoring of platelet counts.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Therapeutic Drug Monitoring: Affecting Factors
01:29Venous Thrombosis III: Interprofessional Care
01:26Transient Ischemic Attack l: Introduction
01:29Hepatic Encephalopathy